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Scaffold molecules interact with multiple effectors to elicit specific signal transduction pathways. CIITA, a
non-DNA-binding regulator of class II major histocompatibility complex (MHC) gene transcription, may serve
as a transcriptional scaffold. Regulation of the class II MHC promoter by CIITA requires strict spatial-helical
arrangements of the X and Y promoter elements. The X element binds RFX (RFX5/RFXANK-RFXB/RFXAP)
and CREB, while Y binds NF-Y/CBF (NF-YA, NF-YB, and NF-YC). CIITA interacts with all three. In vivo
analysis using both N-terminal and C-terminal deletion constructs identified critical domains of CIITA that
are required for interaction with NF-YB, NF-YC, RFX5, RFXANK/RFXB, and CREB. We propose that binding
of NF-Y/CBF, RFX, and CREB by CIITA results in a macromolecular complex which allows transcription
factors to interact with the class II MHC promoter in a spatially and helically constrained fashion.
The major histocompatibility complex (MHC) class II pro-
teins play a central role in the immune response. Extensive
analysis has underscored that much of the fluctuation in class
II MHC antigen expression can be attributed to changes at the
transcriptional level (46, 47). In addition to the class II MHC
molecules themselves, associative accessory molecules that are
necessary for class II antigen MHC function appear to be
controlled in a similar fashion. These associative molecules
include the MHC class II-associated invariant chain (Ii) and
the more recently described DM heterodimer. All class II
MHC, Ii, and DM promoters share the unique presence of
three DNA elements, called W, X, and Y, which are highly
conserved and critical for promoter function (2, 15). The W-
X-Y elements are not only important for constitutive gene
expression in B cells but also critical for inducible gene expres-
sion. In addition to the conservation in sequence, the spacing
between the X and Y elements is highly conserved at approx-
imately two helical turns. Increasing the number of helical
turns between these two elements preserves function, while
disrupting this orientation destroys promoter activation. Our
group previously hypothesized that this restrictive spacing may
be required to align the X and Y elements on the same side of
the DNA helix, thus allowing transcription factors which can
bind these elements to directly interact or to participate in the
assembly of a larger promoter complex (48, 49).
The Y box is a CCAAT motif, and it interacts with NF-Y/
CBF (also known as YEBP/CP-1). NF-Y/CBF is composed of
A, B, and C subunits (26, 27, 57), with the conserved core
sequences of NF-YC (CBF-C) and NF-YB (CBF-A) forming a
histone fold motif similar to the nucleosome subunits H2A and
H2B (1). NF-Y/CBF plays a critical role in opening chromatin
because mutation of the NF-Y/CBF-binding sites in both the
DRA and Ii promoters results in the loss of protein binding
across these promoters in intact cells (24, 54). NF-Y/CBF can
preset chromatin for other transcriptional coactivators, such as
the histone acetylase GCN5, p300, and pCAF (10, 19, 23). The
X box is a bipartite sequence. X1 is bound by the trimeric
transcription factor, RFX, formed by RFX5, RFXAP, and
RFXANK/RFXB (12, 28, 45). The lack of RFX results in
several subclasses of bare lymphocyte syndrome (BLS), a se-
vere immunodeficiency attributed to the lack of class II MHC
expression. RFX is required for both the constitutive and
gamma interferon (IFN-g) induction of class II MHC expres-
sion (5). The X2 element binds a protein complex, X2BP,
which has been recently identified as the CREB protein (29).
Despite the extensive demonstration that X and Y box-
binding proteins are important for class II MHC regulation,
these proteins are constitutively expressed and cannot explain
the cell-, tissue-, developmentally, and cytokine-inducible ex-
pression of class II MHC. A major puzzle of class II MHC gene
control was solved by the seminal isolation of the class II
transactivator, CIITA (43). CIITA was identified by comple-
mentation cloning of the DR2 mutant B-cell line, RJ2.2.5.
CIITA complemented not only the in vitro-generated RJ2.2.5
but also cell lines from type II (group A) BLS patients. CIITA
is now shown to be required for IFN-g, interleukin-4 (IL-4),
IL-10, IL-1, transforming growth factor b, and lipopolysaccha-
ride control of class II genes (4, 5, 18, 32, 44). CIITA is itself
not a DNA-binding protein and has both conventional and
unconventional features for a transcriptional regulator. It has
acidic residues similar to those of other transcriptional activa-
tion domains (37, 58) followed by stretches rich in proline,
serine, and threonine. CIITA also has a nuclear localization
sequence as demonstrated by the analysis of a group A BLS
cell line which lacks an exon-encoding sequence critical for
nuclear translocation (9). However, unlike conventional tran-
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scription factors, CIITA does not contain homologies to
known DNA-binding domains, and it does not appear to bind
any of the class II MHC promoter elements. It also has three
regions similar to GTP-binding consensus motifs that are im-
portant for function (6, 17, 55). These motifs can be replaced
with their counterparts from Ras, a prototype GTPase and G
protein. The presence of a functional GTP-binding motif in a
transcription factor is first described for CIITA; thus, it may
represent a novel class of transcriptional coactivator.
A crucial remaining question is the mode of action of
CIITA. The most likely scenario is that CIITA interacts with
RFX and NF-Y/CBF. Interaction between CIITA and RFX5
has been detected using an in vitro cell-free system, where
CIITA and RFX5 were placed in a two-hybrid system to reveal
functional interactions (39). This report shows that CIITA
does not interact with NF-YA but does interact with the
NF-YB and NF-YC subunits of NF-Y/CBF and the RFX5 and
RFXANK/RFXB subunits of RFX, in addition to CREB. De-
tailed mapping analyses identified the distinct sequences
within CIITA that are required for interaction with these first-
tier transcription factors. RFXANK requires the N-terminal
residues 1 to 335 of CIITA for interaction, while RFX5 re-
quires the adjacent residues 336 to 612. Similarly, NF-YC
requires residues 218 to 335, while NF-YB requires the adja-
cent residues 518 to 612. The C-terminal half of the molecule
is not involved in these interactions. A model is suggested
where RFX and NF-Y/CBF interact with CIITA in a highly
specific fashion, to result in the stereospecific alignment of X
and Y elements. This further suggests that CIITA may serve as
a scaffold for the specific recruitment and binding of DNA-
binding proteins, to cause the selective activation of class II
MHC, Ii, and DM promoters.
MATERIALS AND METHODS
Plasmid constructs. The construction of the wild-type DRA-CAT reporter
gene and its mutant forms W(X15)Y, W(X110)Y, (W15)XY, and (W110)XY
was described previously (49). DRA-CAT contains 141 bp of DRA promoter
fused to the chloramphenicol acetyltransferase (CAT) gene. W(X15)Y,
W(X110)Y, (W15)XY, and (W110)XY mutant forms of DRA-CAT contain
either a 5-bp TGCAG or a 10-bp TGCAGGTCGC insertion. The constructs
mutW, mutX, and mutY have been described previously (30).
The cDNA for cloning RFXANK/RFXB was generated using mouse mam-
mary tumor virus reverse transcriptase (Bio-Rad) and random hexamers (Gibco-
BRL) as primers from Raji total RNA isolated using the TRIzol reagent (Gibco-
BRL). The cDNA was further amplified by PCR using oligonucleotide primers
based on the published human RFXANK/RFXB sequence (28, 31). The DNA
fragment generated was introduced into pcDNA3 mammalian cell expression
vector (Invitrogen) by insertion into the EcoRV cloning site. The construct was
characterized by automated DNA sequencing. With the RFXANK/RFXB as
parent template, FlagRFXANK and mycRFXANK were constructed with the
addition of Met-Flag and Met-myc 59 to the original initiator start codon.
FlagRFX5 and mycRFX5 were respectively produced from RFX5 (3) similar to
the construction of epitope-tagged RFXANKs. The NotI-digested mycRFX5
PCR fragment was directly introduced into EcoRV- and NotI-digested pcDNA3,
while FlagRFX5 was ligated into pcDNA3 via shuttling through PCRII (In-
vitrogen).
Using mycRFX5 as a template, C-terminal truncation mutants mycRFX5
(1–570), mycRFX5(1–537), mycRFX5(1–501), mycRFX5(1–466), mycRFX5(1–
427), mycRFX5(1–343), mycRFX5(1–307), mycRFX5(1–263), mycRFX5(1–225),
mycRFX5(1–200), mycRFX5(1–169), and mycRFX5(1–135) were constructed by
PCR using cloned Pfu DNA polymerase (Stratagene) with a common upper-strand
primer complementary to pcDNA3 (59-GCCCTCTAGATGCATGCTCG) and dif-
ferent lower-strand primers distributed along the human RFX5 sequence to intro-
duce stop codons. The PCR-amplified fragments were subjected to HindIII
restriction enzyme digestion and ligation into a HindIII-EcoRV-cleaved pcDNA3
fragment. Flag-tagged RFX5 N-terminal mutants FlagRFX5(46–617), FlagRFX5
(79–617), FlagRFX5(121–617), FlagRFX5(155–617), and FlagRFX5(162–617) were
generated in a way similar to the construction of C-terminal mycRFX5 deletions
using upper-strand primers that complemented different regions of the RFX5 se-
quence, initiating at the position indicated in their names.
Full-length FlagNF-YA, FlagNF-YB, and mycNF-YB were generated using
the previously described pGEM-GST-NF-YAq and pGEM-GST-NF-YB (25, 50,
54) as templates. Flag and myc sequences were introduced by PCR. The EcoRV-
XhoI-digested PCR-amplified fragments were ligated into pcDNA3. The con-
struction of full-length FlagNF-YC and mycNF-YC was similarly performed.
PCR-amplified FlagNF-YC and mycNF-YC used CBF-C (41) as a template, and
the products were introduced into pcDNA3 at the EcoRI site with the correct
orientation verified by restriction enzyme cutting. The EcoRI-XhoI-digested
PCR fragment of myc-tagged NF-YC was ligated into pcDNA3 cleaved with the
same restriction enzymes.
The construction of FlagCIITA (6) and FlagCIITA(1–1017) (7) has been
described previously. They were produced in the pcDNA3 expression vector
(Invitrogen). Using FlagCIITA as a parent template, stop codons were introduced at
designated residue positions to generate FlagCIITA(1–335), FlagCIITA(1–421),
FlagCIITA(1–444), FlagCIITA(1–518), FlagCIITA(1–612), and FlagCIITA(1–
793) using the QuickChange mutagenesis protocol (Stratagene). FlagCIITA
(1–186) was constructed in a fashion identical to that of FlagRFX5 C-terminal
series truncation mutants using FlagCIITA as template. pUC19-mycCIITA was
generated by ligating overlapping oligonucleotides coding for the myc epitope
tag, MEQKLISEEDL, to the N terminus of the CIITA cDNA and replacing the
original initiator methionine. The EcoRI-SalI mycCIITA insert was transferred
into EcoRI-XhoI-digested pcDNA3. mycCIITA(1–793) and mycCIITA(1–
1017) were constructed by introducing the SacII-XhoI restriction fragments of
FlagCIITA(1–1017) and FlagCIITA(1–793) into mycCIITA SacII-XhoI sites,
respectively. mycCIITA(1–518) and mycCIITA(1–612) were generated by chang-
ing residues 519 and 613 into a stop codon using the QuickChange mutagenesis
kit (Stratagene). Flag epitope-tagged CIITA N-terminal deletions FlagCI-
ITA(88–1130), FlagCIITA(148–1130), FlagCIITA(180–1130), FlagCIITA(218–
1130), FlagCIITA(254–1130), FlagCIITA(300–1130), FlagCIITA(335–1130),
FlagCIITA(518–1130), FlagCIITA(613–1130), and FlagCIITA(706–1130) were
made in a way identical to the construction of Flag-tagged RFX5 N-terminal
deletions.
pcDNA3myc is a generous gift from Yue Xiong, and Rous sarcoma virus
(RSV)-CREB was kindly provided by Shannon Kenney, University of North
Carolina (UNC) Lineberger Cancer Center. All plasmids were purified using a
Qiagen column (Qiagen) prior to transfection. Detailed plasmid construction
information is available upon request.
Antibodies. With the GCG program (GCG, Madison, Wis.) as a search tool,
peptide sequences QDVQKFSDNDKLC (at the N terminus of human RFX5)
and HTEDNKRRTLQRNDC (at the C terminus of human NF-YC) were se-
lected for the production of rabbit anti-RFX5 and rabbit anti-NF-YC antibodies,
respectively. The synthetic peptides were conjugated to keyhole limpet hemocy-
anin (UNC Peptide Synthesis Core Facility) and were used to prepare antisera
(Rockland Immunochemicals Inc.). Monoclonal anti-myc (9E10) was purified
from 9E10 hybridoma culture medium using a protein A/G affinity column
(Pierce). Monoclonal anti-Flag (M5), and monoclonal anti-Flag–agarose were
purchased from Sigma. Rabbit anti-myc and rabbit anti-CREB were obtained
from Santa Cruz. Goat anti-mouse immunoglobulin G (IgG) Dynabeads and
sheep anti-rabbit IgG Dynabeads were from Dynal Corp. (Oslo, Norway).
Transient transfection and CAT assay. Transient transfection and subsequent
CAT assay were performed as described previously (54) using U373-MG cells, a
glioblastoma multiform cell line. Briefly, 10 mg of DRA-CAT reporter plasmid
was cotransfected with 10 mg of CIITA or its vector pcDNA3 into 4 3 106
U373-MG cells by electroporation. Transfected cells were incubated with or
without 500 U of IFN-g per ml. Cells were harvested 48 h later for assay of CAT
levels as described previously (54). The quantitation was performed with a
Molecular Dynamics PhosphorImager. Fold induction is calculated by dividing
the percentage of acetylation in the presence of CIITA or IFN-g by its corre-
sponding controls.
In vitro transcription, translation, and binding assay. Plasmids were in vitro
transcribed and translated using TNT T7 transcription and translation coupled
kit (Promega). For one reaction, 1 mg of each DNA as indicated in each figure
legend was incubated with 40 ml of TNT T7 master mix in the presence of 2 ml
of [35S]Met in a 50-ml reaction volume for 90 min at 30°C. Protein binding
interactions were performed in a 13 TBST environment (1 M NaCl, 40 mM Tris
[pH 7.5], 0.25% Tween 20) in a total volume of 55 ml. After 1 h of incubation, 1.8
mg of monoclonal anti-myc antibody (9E10) was added for 2 h before the
addition of protein G agarose (Pierce) for another 3 h at 4°C. Samples were
washed three times with 13 TBST, prepared according to the standard proce-
dure, and half of the volume was subjected to sodium dodecyl sulfate (SDS)-
PAGE electrophoresis (38). Gels were dried before exposure with X-OMAT film
(Kodak).
Immunoprecipitation and Western blot analyses of in vivo protein-protein
interaction. COS7 cells were cultured in a 37°C incubator with 5% CO2 in
Dulbecco’s modified Eagle’s medium (Sigma) supplemented with 10% fetal
bovine serum. Cells were plated at 9 3 105 cells/100-mm-diameter dish and
allowed to grow for 18 h. Cells were cotransfected with 3 mg of each plasmid as
described in the figure or its legend for each experiment using Fugene 6 (Boehr-
inger Mannheim) according to the manufacturer’s instructions. After 30 to 40 h
of culture, cells were washed twice with 13 phosphate-buffered saline and lysed
with 1.5 ml of cold RIPA buffer (40) (0.1% SDS, 1% NP-40, 1% deoxycholate,
150 mM NaCl, 2 mM EDTA, 0.01 M sodium phosphate [pH 7.2], and 50 mM
NaF) supplemented with a tablet of Complete protease inhibitor cocktail
(Boehringer Mannheim) per 50 ml of solution. Immunoprecipitation and West-
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ern blotting were performed according to standard procedures (38, 40, 42). Blots
were detected by enhanced chemiluminescence (Pierce) using Kodak X-OMAT
film. Detailed information is available upon request.
RESULTS
Regulation of the DRA promoter by CIITA requires the
proper helical orientation of X and Y elements. Previous re-
sults from this laboratory have shown that the regulation of
class II MHC promoters is dependent on the highly specific
arrangement of the W, X, and Y elements. The X and Y
elements are evolutionarily conserved such that they are sep-
arated by a spacer that spans approximately two helical turns of
DNA. The addition of complete helical turns (up to six) to this
spacer does not alter promoter function. In dramatic contrast,
addition or deletion of half-helical turns that would misalign
the X and Y elements destroy the function of this promoter.
Altering the distance between W and X also dramatically de-
creases promoter activity, although this does not depend on
the helical orientation. These results lead to our hypothesis
that X and Y binding proteins may have to bind to the same
side of the DNA for proper direct interaction (48, 49). Fur-
thermore, indirect interaction with a second-tier transcription
factor may also require the stereospecific alignment of these
DNA elements.
CIITA may represent a potential second-tier transcription
factor. To address this hypothesis, experiments were per-
formed to assess if the regulation of a class II MHC promoter
by CIITA also requires stereospecific alignment of X and Y
elements, and if the requirement parallels that of IFN-g-in-
duced promoter activation. The previous reports cited above
showed that class II promoter activation in B-cell lines and by
IFN-g requires stereospecific alignment of these two promoter
elements, while this experiment directly assesses if CIITA has
a similar stereospecific requirement. As shown in Fig. 1, CIITA
and IFN-g induced similar levels of reporter gene expression
under the control of a wild-type DRA promoter (row 1). A
mutation in the W, X, or Y element greatly reduced both
IFN-g- and CIITA-induced promoter activation, as expected.
In contrast, a mutation of the octamer element had little effect.
The addition of half a helical turn (5 bp) to the spacer between
X and Y [construct W(X15)Y] destroyed DRA promoter ac-
tivation by both CIITA and IFN-g, while the addition of one
helical turn (10 bp) [construct W(X110)Y] restored most of
the activity. This indicates that CIITA activates only class II
promoters that maintain helical alignment of the X and Y
elements. The addition of any distance between W and X,
regardless of helical orientation, destroyed promoter activa-
tion by IFN-g. However, only the addition of 10 bp, not 5 bp,
destroyed promoter activation by CIITA. This suggests that
overexpression of CIITA can overcome short-distance changes
between W and X, although the mechanism is unclear. To-
gether, these data suggest that the regulation of a class II MHC
promoter by CIITA requires properly aligned X and Y and, to
a lesser extent, W. It is then plausible that CIITA may serve as
the second-tier protein that binds to RFX, CREB, and NF-Y/
CBF, which in turn recognize X and Y elements.
In vitro interaction of CIITA with NF-YB and -C and RFX5.
A cell-free, in vitro translation system was used to assess if
CIITA interacts with subunits of NF-Y/CBF and RFX. myc-
tagged CIITA (mycCIITA) was cotranslated with either NF-
YA, -B, or -C subunits in the presence of [35S]methionine,
followed by immunoprecipitation with an anti-myc antibody or
preimmune serum (Fig. 2A). Anti-myc precipitated mycCIITA
as expected. The mycCIITA protein did not coprecipitate
NF-YA but did coprecipitate NF-YB and -C (lanes 1, 4, and 7).
Coprecipitated proteins were easily detectable because they
were radiolabeled. Samples treated with preimmune control
serum also show bands corresponding to NF-YB and -C (lanes
2, 5, and 8); these are likely due to nonspecific binding of these
proteins to serum and agarose beads. Based on the amount of
NF-YA, -B, or -C (lanes 3, 6, and 9) that was added to each
reaction, relatively more NF-YC was coprecipitated than NF-
YB. A similar experiment was performed, except that RFX5
was used in place of NF-Y/CBF subunits (Fig. 2B). RFX5 was
also coprecipitated with mycCIITA, in accordance with a pre-
vious study using yeast two-hybrid analysis (39), although a
band was also detected in the control (lane 1). This is a typical
problem that we have noticed with in vitro protein-protein
FIG. 1. Transactivation of the DRA promoter by CIITA requires stereospecifically aligned and/or properly spaced W-X-Y elements. The transactivation of different
DRA promoter mutants by CIITA compared with that by IFN-g is shown. Fold activation is calculated as CAT expression in the presence of CIITA or IFN-g divided
by CAT expression in its absence. Mutated W, X, Y, or octamer sequence is indicated by an “X.” W(X15)Y and W(X110)Y have insertions of 5 and 10 bp, respectively,
between X and Y, while (W15)XY and (W110)XY have insertions of 5 and 10 bp, respectively, between W and X.
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interaction analysis; therefore, we performed most of the fol-
lowing analysis in cell extracts.
CIITA interacts with NF-YB and -C in cells. It is crucial that
any in vitro result is verified with in vivo findings. In tissues and
cell lines tested to date, the detection of endogenous CIITA
protein has been difficult due to its extremely low level of
expression (5). To overcome this problem, cells were cotrans-
fected with a CIITA expression vector and NF-YA, -B, or -C
subunits. The CIITA gene was tagged with a myc epitope,
while the NF-YA, -B, and -C subunits were tagged with a Flag
epitope. As a control for loading, the NF-Y/CBF subunits from
total lysate were detected by immunoblotting with anti-Flag
(Fig. 3A), and CIITA was detected by immunoblotting with
anti-myc (Fig. 3B). To determine if CIITA interacts with NF-
Y/CBF subunits, cotransfected cells were lysed, and the cell
lysate was incubated with the anti-myc antibody to precipitate
the CIITA protein. The NF-Y/CBF subunits which coprecipi-
tated with CIITA are shown in Fig. 3C. Immunoprecipitation
of CIITA coprecipitated NF-YB (lane 4) and NF-YC (lane 6),
but not NF-YA (lane 2). An empty vector control in place of
the CIITA expression vector did not pull down NF-Y/CBF
subunits (lanes 1, 3, and 5). A prolonged exposure of the
portion of the gel that contained the NF-YA protein revealed
a weak band corresponding to NF-YA. This indicates that the
interaction of CIITA with NF-YA is very weak. These findings
mirror that of the cell-free system shown in Fig. 2.
Mapping of the sequence within CIITA that is required for
association with the NF-YB or -C subunit. One working model
is that distinct domains of CIITA function together to serve as
a scaffold upon which DNA-binding transcription factors im-
portant in class II MHC gene transcription can be organized.
To explore this possibility, it was necessary to determine the
sequences within CIITA that are important for such interac-
tions. This was achieved by constructing a series of CIITA
deletion mutants and examining their association with the NF-
Y/CBF subunits. As shown in Fig. 4A, six nested, C-terminal
deletion mutants of CIITA were constructed. The amino acid
sequence which remains in each construct is indicated; thus,
CIITA(1–335) contains amino acids 1 through 335. Each Flag-
CIITA mutant was cotransfected with mycNF-YB or mycNF-
YC. The expression of mycNF-YB (Fig. 4) or mycNF-YC (Fig.
5) was confirmed by immunoblotting of total cell lysate with an
anti-myc antibody while the CIITA protein was detected using
an anti-Flag antibody (Fig. 4B and E). NF-YB was coprecipi-
tated with wild-type FlagCIITA and FlagCIITA(1–1017), -(1–
793), and -(1–612) but not with FlagCIITA(1–335) (Fig. 4C).
FlagCIITA(1–518) and -(1–444) consistently coprecipitated
very small quantities of NF-YB. This indicates that CIITA(1–
612) is required for optimal interactions with NF-YB. To fur-
ther delineate the boundary of the N-terminal sequence of
CIITA that is required for interaction with NF-YB, an addi-
tional four deletion mutants were made (Fig. 4D). Cell lysates
were again analyzed for the expression level of recombinant
molecules, and they were similar to wild-type controls (Fig. 4D
and E). Deletion construct FlagCIITA(518–1130) retained in-
teractive capacity, while FlagCIITA(613–1130) did not (Fig.
4F). This delineates the CIITA residues required for interac-
tion with NF-YB as amino acids 518 to 612 (Fig. 4G). For the
analysis of all deletion mutants, we caution that these inter-
pretations are formed in the absence of structural information.
A similar analysis was performed with NF-YC. NF-YC co-
precipitated with all the CIITA C-terminal deletion mutants
except FlagCIITA(1–186) (Fig. 5A to C). Additional analysis
FIG. 2. CIITA interacts with the B and C subunits of NF-Y/CBF and with
RFX5 in a cell-free system. (A) CIITA interacts with NF-YC and NF-YB.
35S-labeled myc-tagged CIITA (mycCIITA) and 35S-labeled FlagNF-YA (lanes 1
and 2), FlagNF-YB (lanes 4 and 5), or FlagNF-YC (lanes 7 and 8) were produced
by cotranslation of these products. The minus signs in the chart indicate the
presence of either an appropriate empty control plasmid or an appropriate Ig
control. The mixtures were immunoprecipitated with anti-myc (9E10) antibody
(lanes 1, 4, and 7) or preimmune serum (lanes 2, 5, and 8) and anti-mouse IgG
agarose. In vitro-translated 35S-labeled FlagNF-YA (lane 3), FlagNF-YB (lane
6), and FlagNF-YC (lane 9) were included to show the electrophoresis pattern of
the expected translation products. The translated CIITA appears in the upper
part of lanes 1, 4, and 7. Coprecipitated NF-YB (lane 4) and NF-YC (lane 7) are
seen comigrating with the input product shown in lanes 6 and 9. (B) CIITA
interacts with RFX5 in vitro. The experiment was performed similarly to that
described for panel A, except that the in vitro-translated FlagCIITA was not
radiolabeled, and only the RFX5 protein was radiolabeled. Lane 2 shows a weak
band indicative of RFX5 which coprecipitated with the CIITA protein. Lane 3
shows the electrophoresis pattern of RFX5.
FIG. 3. CIITA interacts with NF-YB–NF-YC and RFX5 in cells. (A and B)
Cells (9 3 105) were cotransfected with 3 mg of mycCIITA or its corresponding
control vector pcDNA3myc and 3 mg of FlagNF-YA, FlagNF-YB, or FlagNF-YC
as indicated. Cells were lysed with 1.5 ml of RIPA buffer 36 h after transfection,
and 25 ml of the samples was subjected to SDS–10% polyacrylamide gel elec-
trophoresis resolution. The expression of mycCIITA and FlagNF-YA, FlagNF-
YB, or FlagNF-YC was analyzed by Western blotting using either anti-Flag (M5)
(A) or anti-myc (9E10) (B) antibodies, which respectively detect the NF-Y
subunits or CIITA. IB, immunoblotting. (C) Half of the cell lysate described for
panel A was incubated with 3.7 mg of anti-myc (9E10) antibody for 1.5 h. The
immunocomplexes were incubated at 4°C overnight with 15 ml of anti-mouse IgG
Dynabeads. The association of CIITA with NF-YA (lane 2), NF-YB (lane 4), or
NF-YC (lane 6) was studied by Western blotting using the anti-Flag (M5)
antibody. IP, immunoprecipitation. (D) Prolonged exposure of the blot in panel
C shows a weak interaction between CIITA and NF-YA (asterisk). H and L
designate heavy and light chains of Ig, respectively. (E) CIITA interacts with
RFX5. Similar to the experiments performed for panels A to D, FlagRFX5 was
cotransfected with either mycCIITA or pcDNA3myc. Cell lysate was immuno-
precipitated using the anti-myc (9E10) antibody. The associated FlagRFX5 was
detected by anti-Flag (M5) antibody immunoblotting.
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with the N-terminal deletion constructs shows stronger inter-
actions up to FlagCIITA(218–1130) (Fig. 5D and E). A pre-
cipitous drop in interaction was observed with a further dele-
tion (Fig. 5F, lane 7) despite a robust level of protein
expression. It is notable that FlagCIITA(218–1130) has a lower
level of expression than that of the other constructs (Fig. 5E)
and yet interacted the most strongly (Fig. 5F, lane 6). The
appearance of the signal in this sample is due to its intensity,
which depleted the substrate. One interpretation is that the
sequences at the N terminus preclude optimal interaction, and
their removal in FlagCIITA(218–1130) caused enhanced inter-
action. Together, these results indicate that residues 218 to 335
of CIITA are required for optimal interaction with CIITA.
They also map the NF-YC and NF-YB interaction sites to
adjacent but different domains. All the biochemical association
experiments in Fig. 5 and the following figures were repeated
at least two more times.
Mapping of sequences required for the association of CIITA
and RFX5. A previous study used CIITA as a bait and RFX5
as the test molecule in a yeast two-hybrid system to detect their
interaction. Here we used an in vivo approach to address this
issue and additionally mapped the interaction sites on both
molecules. The approach is similar to that used in Fig. 3 to 5.
The RFX5 protein was precipitated with an anti-myc antibody,
and associated CIITA was detected by immunoblotting with
the anti-Flag antibody. Figure 6A shows the expression of the
nested CIITA deletion mutants in total cell lysate, and Fig. 6B
shows the expression of RFX5 protein. CIITA(1–335) through
CIITA(1–518) did not coprecipitate FlagRFX5, while
mycCIITA(1–612) did. The inclusion of additional sequences
in FlagCIITA(1–793) resulted in more coprecipitated proteins.
This indicates that FlagCIITA(1–612) contains the minimal
sequence required for interaction with RFX5, while additional
sequences in CIITA(1–793) further enhanced this association.
To further delineate the boundaries of interaction, a series of
CIITA N-terminal mutations were also tested. As shown in
Fig. 6D and E, FlagCIITA(335–1130) retained interaction with
RFX5, while further deletion constructs did not. These data
map the boundaries within CIITA that are required for inter-
action with RFX5 as residues 335 to 612 (Fig. 6G).
To identify the sequences within RFX5 that are required for
interaction with CIITA, a series of 17 RFX5 deletion con-
structs were produced: 11 are C-terminal mutants, and 6 are
N-terminal mutants (Fig. 7). The expression of RFX5 in cell
lysate was detected by immunoblotting with an anti-RFX5
antibody, and CIITA was detected using an anti-Flag antibody
in Fig. 7A to C. Ten of these 11 RFX5 deletion mutants
associated with CIITA; only mycRFX5(1–169) did not associ-
FIG. 4. CIITA residues 518 to 612 interact with NF-YB in cells. To map the domain of CIITA that is required for interaction with NF-YB, a series of FlagCIITA
C- and N-terminal deletion mutants were constructed. Each sample was cotransfected with 3 mg of FlagCIITA or its mutants and 3 mg of a myc-tagged NF-YB subunit.
The subsequent immunoprecipitation, electrophoresis, and Western blotting procedures were performed as described in the Fig. 3 legend. (A) Expression of NF-YB
in total cell lysate was detected by immunoblotting with the rabbit anti-myc antibody. (B) Expression of FlagCIITA and its mutants in total lysate was confirmed by
immunoblotting with the anti-Flag (M5) antibody. (C) FlagCIITA and its C-terminal deletion mutants were used to coprecipitate mycNF-YB, which was detected by
rabbit anti-myc antibody. (D to F) The same as panels A to C, respectively, except that N-terminal deletion mutants were used. (G) The two constructs which delineated
the residues within CIITA that interacted with NF-YB. The black area marks the overlapping residues shared by these two constructs.
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ate with CIITA. This indicates that mycRFX5(1–200) contains
the minimum sequence required for association with CIITA.
The N-terminal mutants were tested by immunoprecipitat-
ing mycCIITA with the appropriate antibody and then immu-
noblotting with anti-Flag antibody to detect the RFX5 protein
(Fig. 7D to F). FlagRFX5(121–617) coprecipitated with CIITA
(lane 6), while further deletions eliminated this interaction
(lanes 7 to 9). This delineates the boundaries of the RFX5
domain that are required for interaction with CIITA as RFX5
residues 121 to 200.
Mapping of sequences within CIITA that are required for
association with RFXANK/RFXB and CREB. A similar strat-
egy was used to map the domain within CIITA that is required
for association with RFXANK/RFXB. The panel of Flag-
tagged CIITAs was not used in this initial experiment as we
encountered technical problems in the recognition of myc-
tagged RFXANK/RFXB with anti-myc antibody. Instead, a
new panel of Flag-tagged RFXANK and myc-tagged CIITA
had to be constructed. As shown in Fig. 8A to C, FlagRFXANK
and mutant forms of CIITA were detected in total cell lysate,
and FlagRFXANK precipitated all mutant forms of mycCIITA.
This indicates that residues 1 to 518 of CIITA interact with
RFXANK. To better delineate the region that is required,
additional C-terminal deletions were tested (Fig. 8D to F). In
these latter experiments, we overcame the technical problems
in the recognition of mycRFXANK by anti-myc antibodies.
The experiment indicates that the N-terminal 335 residues of
CIITA retained interaction with RFXANK but that a deletion
mutant containing only the N-terminal residues 1 to 148 lost
this interaction.
CREB is the protein that interacts with the 39 half of the X
box (also known as the X2 box). To determine if CREB asso-
ciates with CIITA, cells were cotransfected with a plasmid
containing the CREB gene driven by the RSV promoter and
Flag CIITA or its various deletion mutants. The expression of
CREB and CIITA is shown in Fig. 9A and B, while the copre-
cipitated CIITA is shown in Fig. 9C. FlagCIITA(1–793)
strongly associated with CREB, while FlagCIITA(1–612) as-
sociated weakly. Further deletion mutants did not associate
with CREB. This indicates that FlagCIITA(1–793) contains
the sequences which exhibit optimal association with CREB,
while CIITA(1–612) can still associate with CREB.
DISCUSSION
The past decade has witnessed an exponential increase in
the number of proteins identified as important in signal trans-
duction and in transcription; however, one of the greatest
challenges that remain is understanding how these individual
components can be assembled in different ways to produce
distinct biological effects. The mitogen-activated protein ki-
nase provides an excellent example of this dilemma. In yeast,
FIG. 5. CIITA residues 218 to 335 interact with NF-YC in cells. To map the domain of CIITA that is required for interaction with NF-YC, a series of FlagCIITA
C- and N-terminal deletion mutants were constructed. The experiment was performed similarly to that for Fig. 4. (A) Expression of NF-YC in total cell lysate was
detected by immunoblotting with the rabbit anti-myc antibody. (B) Expression of FlagCIITA and its mutants in total lysate was confirmed by immunoblotting with the
anti-Flag (M5) antibody. (C) FlagCIITA and its C-terminal mutants were used to coprecipitate mycNF-YC, which was detected by rabbit anti-myc antibody. (D to F)
The same as panels A to C, respectively, except that N-terminal mutants were used. (G) The two constructs which delineated the residues within CIITA which interacted
with NF-YC. See the Fig. 3 legend for more details.
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these proteins have been linked to multiple signaling pathways
including responses to mating pheromone, invasive growth,
cell integrity, sporulation, and response to high osmolarity (16,
33, 52). Some of these kinase cascades involve the formation of
a macromolecular complex, Ste5, which serves as a scaffold
interacting with kinases of the pheromone mating pathway,
thus promoting this pathway while diminishing the usage of
these kinases in other pathways (22). In mammalian cells,
scaffolding proteins such as the JNK-interacting protein have
been found which preferentially promote the assembly of spe-
cific mitogen-activated protein kinases, to result in specific
signal transduction pathways (11, 51, 56). Such a system has
not been proposed for a protein involved in transcriptional
activation, although it seems a logical and elegant possibility.
In this report, we show the tour de force analysis of CIITA’s
association with multiple transcription factors that bind the
class II MHC promoter. Although such associations have been
proposed, and the interaction with RFX5 has been analyzed,
we believe that, for the field to advance, a more detailed
analysis of all components is necessary. The results show that
CIITA associates with NF-Y/CBF, RFX, and CREB. All three
are ubiquitously expressed DNA-binding factors which recog-
nize the prototype class II MHC promoter elements, but by
themselves, these three factors are insufficient for the induc-
tion of class II MHC promoter. CIITA is additionally required.
The data presented here suggest that assembly of the complex
formed by the interaction of CIITA–NF-Y/CBF–RFX–CREB
is an important step which preferentially brings together the
DNA-binding proteins to increase their localized concentra-
tion at the site of a class II MHC promoter (Fig. 10A). Thus,
by this definition, CIITA may serve as a transcriptional scaffold
which enhances the assembly of a class II MHC-specific set of
DNA-binding proteins.
The primary strategy is to utilize a nested series of CIITA
deletion constructs to map amino acid sequences that are re-
quired for interaction with DNA-binding proteins. In one par-
ticular case, a nested series of RFX5 deletion constructs were
also used. It is well appreciated that the results obtained with
deletion constructs have to be interpreted with caution, be-
cause deletions may result in secondary or tertiary structural
changes without removing the actual interaction sites. With
this critical caveat and the necessity for future refined mu-
FIG. 6. CIITA residues 335 to 612 interact with RFX5 in cells. To map the domain of CIITA that is required for interaction with RFX5, a series of FlagCIITA
C- and N-terminal deletion mutants were constructed. The experiment was performed similarly to that for Fig. 4. (A) Expression of FlagCIITA and its mutants in total
lysate was confirmed by immunoblotting with the anti-Flag (M5) antibody. (B) Expression of RFX5 in total cell lysate was detected by immunoblotting with the rabbit
anti-RFX5 antibody. (C) FlagCIITA was coprecipitated with anti-myc and detected by immunoblotting with anti-Flag antibodies. (D to F) Similar to panels A to C,
respectively, except that N-terminal mutants were used. (G) The two constructs which delineated the residues within CIITA which interacted with RFX5. See the Fig.
3 legend for more details.
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tagenesis in mind, the sequences within CIITA that are re-
quired for interaction with NF-YB, NF-YC, RFX5, RFXANK/
RFXB, and CREB were mapped. It is of interest to point out
that CIITA interacts with NF-YB and -C but only minimally
with NF-YA. In fact, the interaction with NF-YC appears to be
the strongest, although quantitative measures and kinetics
analyses are necessary to reach a definite conclusion. NF-YB
and NF-YC both contain transactivator domains which can
interact with basal transcription factors (8). Furthermore, the
NF-YB subunit interacts with the coactivator for p300 (13).
Together with the current finding, it appears that NF-YB and
NF-YC interact with a number of factors.
The interaction of RFX5 with CIITA agrees with and ex-
tends previous findings using a yeast two-hybrid system (39).
The site within RFX5 that is minimally required for interaction
with CIITA lies between amino acids 121 and 200, thus defin-
ing a 79-amino-acid stretch that is important for interaction
with CIITA. Conversely, the sequences within CIITA which
are required to interact with RFX5 have not been previously
studied, and it has been shown that they include residues 335
to 612. Likewise, the interaction of RFXANK/RFXB with CIITA
has not been described previously, and they require CIITA
residues 1 to 335.
It is most interesting that RFX5 and RFXANK/RFXB in-
teract with adjacent but not overlapping regions of CIITA and
that this pattern is also observed for NF-YB and NF-YC (Fig.
10B). It is likely that this binding of NF-Y and RFX subunits
to adjacent N-terminal domains of CIITA results in a high
local concentration of these DNA-binding proteins. This high
concentration enhances the interaction of NF-Y and RFX,
which has been shown to be an important component of class
II promoter activation.
We appreciate the caveat that if two proteins interact with
the same residues within CIITA, then the possibility exists that
one of the two may be binding directly while the other binds
indirectly through the first. The construct CIITA(1–612)
yielded a much weaker association with RFX5. Interestingly,
this pattern of greater association with CIITA(1–793) and
weaker association with CIITA(1–612) is identical for RFX5
and CREB. More-specific mutagenesis is necessary to deter-
mine if the CREB and RFX interaction sites are identical. If
they are distinct, then it is more likely that these two molecules
are directly interacting with CIITA. If they are identical, then
it is possible that RFX5 and CREB are associated in vivo and
that they are interacting with CIITA as a unit. In other words,
only one of these two molecules is interacting directly with
CIITA, while the other is indirectly interacting with CIITA
through association with its partner, either RFX5 or CREB.
The interaction of CIITA with the DNA-binding transcrip-
tion factors which specifically bind class II MHC promoters
explains much, but not all, of the earlier observations in the
field. Earlier work revealed that the class II MHC promoter
FIG. 7. RFX5 residues 121 to 200 interact with CIITA in cells. The sequence within RFX5 required for interaction with CIITA was mapped using a combination
of either C-terminal RFX5 deletion constructs (A to C) or N-terminal deletion constructs. The experiment was done similarly to that described in the Fig. 4 legend.
(A to C) FlagCIITA was cotransfected with mycRFX5 or its C-terminal mutants. (A and B) Expression of these proteins in cell lysates; (C) coprecipitated protein. The
usage of 10 and 12% gels as indicated in the figure was necessary to optimize the differentiation of different mutant forms of RFX5. (D to F) mycCIITA was
cotransfected with FlagRFX5 or its N-terminal mutants. These panels are similar to panels A to C, respectively. (G) The two constructs which delineated the residues
within RFX5 which interacted with CIITA.
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elements X and Y are highly conserved in evolution and cor-
relatively in function (2, 48). The hypothesis is that proteins
binding to these elements have to interact directly or indirectly
with a second-tier protein in a highly restrained fashion to
cause promoter activation. The interaction of CIITA with NF-
Y/CBF, RFX, and CREB now explains these data and addi-
tionally identifies CIITA as a second-tier protein (see model in
Fig. 10A). As depicted in the model, CIITA interacts with
NF-YB, NF-YC, RFX5, RFXANK/RFXB, and CREB pro-
teins, likely resulting in a higher local concentration of essen-
tial factors at the DRA promoter. These concerted interactions
may also stabilize the macromolecular complex containing all
these transcription factors. In addition to interactions among
CIITA and its partner proteins, interaction between the X and
Y binding proteins also has been reported (34, 54). Specifically,
our group reported that an anti-NF-Y antibody can coprecipi-
tate X1 as well as X2 binding activities. Another group showed
that X and Y binding proteins cooperate in the binding of their
target sites (35). What is yet unknown is whether this consti-
tutes direct or indirect interactions through CIITA. Perfor-
mance of such experiments in cells with or without CIITA
expression would be of interest.
The interaction of CIITA with NF-Y/CBF, RFX, and CREB
also explains the role of these factors in causing promoter
opening in a sequence-specific manner. These previous exper-
iments were all based on genomic footprint analyses which
permitted detection of protein-DNA interactions in intact
cells. The results observed with IFN-g-inducible cell lines show
that the occupancy of class II, Ii, and DM promoters by pro-
teins in vivo is dependent on CIITA, NF-Y/CBF, and RFX
(53). Direct analysis of cell lines which lack either RFX or
CIITA shows a requirement for these two molecules in open-
ing the class II promoters (5, 36, 55). The evidence linking
NF-Y/CBF is less direct, because NF-Y/CBF is a critical factor
for cell growth and proliferation, and mutants lacking this
factor have yet to be identified. An approach was taken to
study the role of NF-Y/CBF by in vivo footprint analysis of a
panel of stable transfectants harboring either wild-type or mu-
tant promoters (24, 54). The results showed that the ablation
of protein binding to a mutated Y element abolished protein
binding throughout the promoter. Mutating X has a lesser but
similar effect. Combined, it appears that CIITA, NF-Y/CBF,
and RFX all play a prominent role in opening the class II
MHC promoter.
One likely explanation of the involvement of CIITA, NF-Y/
CBF, and RFX in promoter opening is provided by the recent
evidence that CIITA and NF-Y/CBF can interact with the
histone acetylases CREB-binding protein (CBP) and p300 (14,
21). Recruitment of the histone acetylases causes histone acet-
ylation and likely results in the opening of promoters. It is
tempting to propose that CIITA brings together DNA-binding
factors to target class II MHC promoters, while tethered CBP
causes histone acetylation, promoter opening, and gene tran-
scription (Fig. 10A). However, one unsatisfactory aspect of this
model, as it applies to most studies of histone acetylase inter-
action with transcription factors, is that the promoter sites are
presumably not accessible prior to histone acetylation, and
therefore it is unclear how a specific DNA-binding factor
would target the class II MHC promoter elements.
Another caveat regarding this model is that in BLS patient-
derived cell lines which lack class II MHC expression, the lack
of RFX is tightly correlated with the lack of in vivo footprints,
while the lack of CIITA is not (20), and yet the class II pro-
FIG. 8. CIITA residues 1 to 335 interact with RFXANK/RFXB in cells. To
map the domain of CIITA that is required for interaction with RFXANK/RFXB,
a series of CIITA C-terminal deletion mutants were used. The experiment was
performed similarly to that for Fig. 4. (A) DNAs used for cotransfection are
indicated in the figure. The expression of FlagRFXANK in total lysate was
validated by immunoblotting with the anti-Flag (M5) antibody. (B) The expres-
sion of mycCIITA and its mutant forms in total lysate was detected by immu-
noblotting with the anti-myc antibody. (C) Anti-Flag M2 antibody plus anti-
mouse IgG Dynabeads was used to immunoprecipitate FlagRFXANK, and
coprecipitated forms of mycCIITA were detected by immunoblotting with the
anti-myc (9E10) antibody. (D to F) Similar to panels A through C, respectively,
except that mycRFXANK and FlagCIITA deletion mutants were used. (G) The
region of CIITA that is sufficient for interaction with RFXANK/RFXB.
FIG. 9. CIITA interacts with CREB. The figure is similar to Fig. 8, except
that RSV-CREB was used in place of FlagRFXANK. Rabbit anti-CREB and
anti-Flag (M5) immunoblottings were utilized to verify the expression of CREB
(A) and that of FlagCIITA or its mutants (B) in total cell lysates. The interaction
of CREB and CIITA was analyzed by immunoprecipitation with rabbit anti-
CREB antibody plus anti-rabbit IgG Dynabeads, followed by immunoblotting
with anti-Flag (M5) (C).
VOL. 20, 2000 INTERACTION OF CIITA WITH NF-Y, RFX, AND CREB 6059
moter is inactive in both cases. It is possible that, in B-cell lines,
another factor can substitute for the function of CIITA or
alternatively that the DNA-binding proteins may be expressed
at a higher level to compensate for the lack of CIITA. None-
theless, CIITA serves an essential function in the transcrip-
tional induction of class II MHC in B cells.
In conclusion, this work provides strong evidence for the in
vivo interaction of distinct domains of CIITA with the DNA-
binding proteins that are involved in class II MHC promoter
activation. Functionally, this explains the observation that CIITA
can activate class II promoters only when X and Y elements
are stereospecifically aligned. Structurally, CIITA may repre-
sent a scaffold protein important in the transcriptional activa-
tion of a class of genes, all coding for proteins important for
class II MHC-mediated antigen processing. At present, it is not
entirely clear if the presence of class II MHC promoter en-
hances these interactions, although we have not noted any
difference in these associations upon the addition of template
DNA in vitro. More detailed and refined analysis will be nec-
essary to address this point.
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